Hendrik-Tobias Arkenau, MD, PhD, discusses the rationale for using TAS-102 (trifluridine/tipiracil; Lonsurf) as a treatment for patients with gastric cancers.
Hendrik-Tobias Arkenau, MD, PhD, executive medical director, executive medical director for Sarah Cannon Research Institute UK, discusses the rationale for using TAS-102 (trifluridine/tipiracil; Lonsurf) as a treatment for patients with gastric cancers.
Arkenau emphasizes that gastric cancers are one of the most common cancers worldwide and are related to both the third and fifth most common cancers. TAS-102 has shown good clinical evidence in patients with colorectal cancer and patients with gastric or gastroesophageal cancer.
Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer
April 16th 2024Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.
Read More